H2N3 influenza vaccine

The **H2N3 influenza vaccine** is an experimental vaccine candidate designed to protect against influenza A(H2N3), a subtype not currently circulating in humans but studied for potential pandemic preparedness due to its historical role in the 1957 pandemic and presence in animal reservoirs. It induces immune responses including neutralizing antibodies against the hemagglutinin (H) protein of the H2N3 strain, aiming to prevent infection from this novel influenza variant. Developed as part of post-approval research efforts, it is administered to healthy adults in clinical studies to assess safety, immunogenicity, and efficacy.